Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Ameet Sarpatwari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass…. Hauptthemen laut MEDLINE: Risk Evaluation and Mitigation, Drug-Related Side Effects and Adverse Reactions, Health Knowledge, Attitudes, Practice. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Risk Evaluation and Mitigation Strategy (REMS) programs mandated by the US Food and Drug Administration involve special interventions such as education or documentation of laboratory testing to ensure that the benefits of certain drugs outweigh their risks. To understand patients’ and caregivers’ perception of and experiences with REMS programs with elements to assure safe use, we conducted semi‐structured interviews from March 2022 to July 2023 with 135 patients or caregivers of patients who had used alemtuzumab (Lemtrada), ambrisentan (Letairis), clozapine (Clozaril), isotretinoin (Accutane), lenalidomide (Revlimid), pegvaliase (Palynziq), or sodium oxybate (Xyrem/Xywav). Participants were recruited through national and regional patient volunteer registries, social media, and patient support groups. Interviews focused on patients’ and caregivers’ knowledge about the REMS program and REMS‐related side effects, treatment initiation, medication access and adherence, pandemic policies, and overall perspectives. Among 135 participants, five key themes emerged: (1) Participants were knowledgeable about REMS‐associated drug risks and requirements; (2) some participants had difficulty finding prescribers, particularly for clozapine; (3) administrative burdens related to REMS implementation were a source of frustration, with satisfaction higher when care coordination support was provided; (4) emotional and logistical challenges were identified with pregnancy‐ and clozapine‐related testing; and (5) participants desired similar engagement around risks not covered in REMS materials. Optimizing system‐level implementation can help improve REMS implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Ameet Sarpatwari, Su Been Lee, Heidi Zakoul, Winta Tekle, Ariel Freedman, Shruti Belitkar, Gita A Toyserkani, Cynthia LaCivita, Esther H Zhou, Kate Heinrich Oswell, Gerald J Dal Pan, Aaron S Kesselheim
Zitieren
APA
Sarpatwari, A., Lee, S. B., Zakoul, H., Tekle, W., Freedman, A., Belitkar, S., Toyserkani, G. A., LaCivita, C., Zhou, E. H., Oswell, K. H., Dal Pan, G. J., & Kesselheim, A. S. (2026). Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70091
Vancouver
Sarpatwari A, Lee SB, Zakoul H, Tekle W, Freedman A, Belitkar S, et al. Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70091
BibTeX
@article{Sarpatwari2026,
author = {Sarpatwari, Ameet and Lee, Su Been and Zakoul, Heidi and Tekle, Winta and Freedman, Ariel and Belitkar, Shruti and Toyserkani, Gita A and LaCivita, Cynthia and Zhou, Esther H and Oswell, Kate Heinrich and Dal Pan, Gerald J and Kesselheim, Aaron S},
title = {Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70091}
}
EUVIMED